What genes are in the MITF-M-regulated melanocyte development pathway?

The MITF-M-regulated melanocyte development pathway involves 40 genes. Key genes include: AGO2, AKT3, ATP6V1B2, BCL2A1, BRCA1, CCNB1, CDC25B, CDK2, CREB1, CREBBP.

MITF-M-regulated melanocyte development

Q: What compounds affect the MITF-M-regulated melanocyte development pathway?

176 compounds in the BiohacksAI corpus have documented interactions with genes in the MITF-M-regulated melanocyte development pathway (Reactome ID: R-HSA-9730414). These compounds target 40 genes within this pathway.

REACTOME PATHWAY

Reactome: R-HSA-973041440 genes176 compounds

The MITF-M-regulated melanocyte development pathway (Reactome ID: R-HSA-9730414) involves 40 genes and is affected by 176 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

AGO2 AKT3 ATP6V1B2 BCL2A1 BRCA1 CCNB1 CDC25B CDK2 CREB1 CREBBP EDNRB EP300 GSK3B HDAC1 IARS1 KARS1 KIT LARS1 MAPK1 MAPK14 MAPK3 MARK3 MC1R MC3R MC5R MET MITF PLK1 RPS6KA1 SERPINE1+10 more

Compounds Affecting MITF-M-regulated melanocyte development

#	Compound	Targets Hit	Studies
1	egcg	—	300
2	alsterpaullone	—	12
3	kenpaullone	—	8
4	Sorafenib	—	300
5	Quercetin	—	300
6	sp600125	—	117
7	Nocodazole Nocodazole is	—	215
8	chrysin	—	300
9	plumbagin [Supplementary Concept]	—	300
10	fisetin	—	78
11	cycloheximide	—	300
12	Bortezomib	—	300
13	Apigenin 5,7,4'-trihydroxy-flavone,	—	300
14	Hexachlorophene	—	300
15	Luteolin 5,7,3',4'-tetrahydroxy-flavone,	—	150
16	Ethidium	—	300
17	Oxytetracycline	—	300
18	Aurintricarboxylic Acid	—	184
19	myricetin-3-O-galactopyranoside [Supplementary Concept]	—	300
20	Oxyphenbutazone	—	300
21	Azacitidine	—	298
22	Azacitidine	—	300
23	Calcimycin	—	216
24	Camptothecin	—	300
25	celastrol	—	300
26	Ciclopirox	—	88
27	Demecolcine	—	246
28	pictilisib	—	25
29	Disulfiram	—	297
30	Dasatinib	—	299
31	pd98059	—	7
32	isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from	—	300
33	withaferin	—	300
34	alpha-MSH	—	300
35	bremelanotide [Supplementary Concept]	—	36
36	melanotan-II [Supplementary Concept] synthetic cyclic heptapeptide,	—	84
37	Cefdinir	—	298
38	colchine	—	2
39	Rutin	—	300
40	Topotecan	—	300
41	Anisomycin	—	247
42	Astemizole Antihistamine drug now withdrawn from	—	280
43	Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.	—	300
44	Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.	—	300
45	juglone hydroxylase [Supplementary Concept] catalyzes	—	279
46	Niclosamide	—	299
47	Podophyllotoxin	—	14
48	Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.	—	300
49	torin 1	—	10
50	vinblastine sulfate	—	81

About the MITF-M-regulated melanocyte development Pathway

The MITF-M-regulated melanocyte development pathway is catalogued in Reactome (ID: R-HSA-9730414) and involves 40 genes. In the BiohacksAI corpus, 176 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include AGO2, AKT3, ATP6V1B2, BCL2A1, BRCA1.